Conclusion:
The main point is that there are several patients with PCP belonging to
categories not generally recommended to be treated with prophylactic
cotrimoxazole and one of these categories are AML patients. Data in
literature are so limited and sparse in association of pneumocystis in
patients with AML. It seems that affected patients appear to have a
clear resistance to PCP infection despite chemotherapy and bone marrow
suppression due to the preservation of a specific immunological milieu
in the lung. In fact, may be due to immunological stability of the lungs
that remains intact. Further studies can determine the risk of PCP in
patients with AML.
Declaration of Conflicting Interests: The authors declared no
potential conflicts of interest with respect to the research,
authorship, and/or publication of this article.
Funding : The authors received no financial support for the
research, author-ship, and/or publication of this article.